Morgan Stanley lowered the firm’s price target on Cabaletta Bio (CABA) to $14 from $22 and keeps an Overweight rating on the shares. The firm sees a continuation of U.S. small-to-mid cap biotech’s outperformance in 2026 as commercial names transition from “capital consumers to producers” and Large Cap Biopharma faces a looming patent cliff, the analyst tells investors in an outlook note for the group.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CABA:
- Cabaletta Bio’s treatment of myasthenia gravis granted FDA orphan designation
- Cabaletta Bio: Promising Progress and Strategic Timelines Drive Buy Rating
- Cabaletta Bio Advances in Autoimmune Therapy Development
- Cabaletta Bio: Strong Financial Position and Strategic Clinical Advancements Justify Buy Rating
- Cabaletta Bio: Promising Clinical Progress and Strategic Advancements Drive Buy Rating